ClinicalTrials.Veeva

Menu

Pharmacokinetics of Caspofungin

M

Medical University of Lublin

Status

Completed

Conditions

Fungal Infection
Critical Illness
Septic Shock

Treatments

Drug: Caspofungin

Study type

Observational

Funder types

Other

Identifiers

NCT03399032
KE-0254/330/2017

Details and patient eligibility

About

The objective of this study is to describe the pharmacokinetics of standard doses of caspofungin in critically ill patients.

Full description

This is a prospective observational study performed on critically ill patients. Inclusion criteria are: severe sepsis on admission requiring broad-spectrum antibiotics. Both medical and surgical patients will be included. Any type of infections will be included (pulmonary, abdominal, urinary tract, etc.) Antibiotics regimen includes: broad spectrum anti-bacterial antibiotics plus caspofungin (70 mg i.v. on the first day day, and 50 mg i.v. on the consecutive days, once daily.

Blood samples (3 mL) will be collected 2, 4, 8,12 and 24 hours after each dose of caspofungin for 3 consecutive days. The standard arterial canula will be used to obtain samples.

30 minutes after each sample collection, blood will be centrifuged for 10 minutes at 3,000 rpms. Subsequently, supernatant will be collected and frozen.

Serum caspofungin concentration will be measured with high performance liquid chromatography.

Each patient's hemodynamics parameters will be recorded with the use of transpulmonary thermodilution technique (PICCO). Other therapies i.e.: ventilatory support, sedation, an antifungal agent will be given as required.

Enrollment

33 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who require ICU treatment due to severe sepsis age
  • 18-80 years
  • an eligible consent obtained from the patient or his/her attendant

Exclusion criteria

  • allergy to caspofungin
  • lack of consent to participate in the study
  • age of patients below 18 or above 80 years

Trial design

33 participants in 1 patient group

Caspofungin
Description:
Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day
Treatment:
Drug: Caspofungin

Trial contacts and locations

1

Loading...

Central trial contact

Mirosław Czuczwar, M.D., PhD; Michał Borys, M.D., PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems